International Journal of Hematology and Oncology 2023, Vol 33, Num 4 Page(s): 001-009
Angiotensin Converting Enzyme (ACE) Insertion/Deletion (I/D) Gene Polymorphisms in Leukemic Hematopoiesis

Ibrahim AKALIN1, Ebru KOCA2, Halil G. KARABULUT1, Ibrahim C. HAZNEDAROGLU2, Deniz CETINER2, Mutlu HAYRAN3, Ibrahim K. ONAL4, Osman I. OZCEBE2, Ajlan TUKUN1

1Ankara University Faculty of Medicine, Department of Medical Genetics, Ankara, TURKEY
2Ankara University Faculty of Medicine Department of Internal Medicine, Hematology Unit, Ankara, TURKEY
3Ankara University Faculty of Medicine, Department of Preventive Oncology, Ankara, TURKEY
4Hacettepe University Faculty of Medicine, Department of Internal Medicine, Ankara, TURKEY

Keywords: Angiotensin converting enzyme, Local renin-angiotensin system, ACE I/D gene polymorphism, Angiotensin II, Leukemic hematopoiesis
Local bone marrow renin-angiotensin system (RAS) is an autocrine-paracrine system affecting normal and neoplastic hematopoiesis. Angiotensin converting enzyme (ACE) converts angiotensinogen-I to its physiologically active peptide angiotensin-II, which stimulates proliferation and differentiation of hematopoietic stem cells through angiotensin II type 1 receptors. We investigated the ACE insertion/deletion (I/D) gene polymorphisms in patients with hematological malignancies including acute and chronic leukemia, myelodysplastic syndrome and multiple myeloma. Our results showed that 80.4% of the patients represented ID/II genotype, whereas it was 55.9% of the control group and 3.2 fold increased disease risk in the existence of insertion allele (ID/II). This is the first study demonstrating possible effects of ACE I/D gene polymorphism of the local bone marrow RAS components on leukemic hematopoiesis.